• Vaccine Name: AdH5-FluA NP
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Product Name: AdC7 encoding NP from Influenza A virus (A/Puerto Rico/8/34(H1N1))
• Vaccine Ontology ID: VO_0004178
• Type: Recombinant vector vaccine
• Status: Research
• Antigen: Influenza A virus (A/Puerto Rico/8/34(H1N1)) NP nucleocapsid protein
• NP from Influenza A virus (A/Puerto Rico/8/34(H1N1)) gene engineering:
  • Type: DNA vaccine construction
  • Description: The nucleotide sequence encoding the H1N1 influenza A virus NP (A/Puerto Rico/8/34/Mount Sinai, GenBank accession number AF389119.1) was codon optimized and completely synthesized (Celtek Genes, Nashville, TN). An expression cassette (approximately 2.5 kb) composed of the human cytomegalovirus early promoter, the codon optimized influenza A NP coding sequence and the bovine growth hormone polyadenylation signal was inserted in place of an E1 deletion in Ad5 or chimpanzee adenovirus Pan 7 (simian adenovirus 24) by the construction of plasmid molecular clones. The recombinant adenoviruses (AdH5-FluA NP and AdC7-FluA NP, respectively) were rescued by transfecting the plasmids into HEK 293 cells (Roy et al., 2007).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: The chimpanzee adenovirus vector AdC7-FluA NP and the human Ad5 vector AdH5-FluA NP, both expressing the NP from H1N1 strain A/PR/8/34, were used to vaccinate BALB/c mice. Mice were sedated with intra-peritoneal ketamine/xylazine, and the total adenovirus dose (10^11 viral particles per mouse) divided into two 25 μl injections given intra-muscularly to the hind leg tibialis anterior (Roy et al., 2007).
• Challenge Protocol: Mice were anesthetized in an atmosphere of 5% isoflurane and challenged with influenza A/PR/8/34, influenza A/Vietnam/1203/04 or influenza A/Hong Kong/483/1997 in 50 μl MEM/BSA, via the intra-nasal route (Roy et al., 2007).
• Efficacy: A simian adenovirus 24 (AdC7) vector expressing the influenza A/Puerto Rico/8/34 NP was tested for its efficacy in protecting BALB/c mice against two H5N1 strains. When tested in a mouse challenge model, there was a significantly improved survival rate following challenge with the Vietnam/1203/04 strain of H5N1 that has caused human outbreaks (Roy et al., 2007).